查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538529

胜胜肽和寡核苷酸 CDMO 市场报告：2030 年趋势、预测和竞争分析

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

胜胜肽/寡核苷酸CDMO趋势与预测

预计到2030年，全球胜肽寡核苷酸CDMO市场将达到约50亿美元，2024年至2030年的复合年增长率为11.3%。该市场的主要驱动力是定制医疗的日益普及、对罕见疾病的兴趣日益浓厚以及对胜肽抗病毒药物的日益关注。全球胜肽寡核苷酸 CDMO 市场的未来充满希望，製药和生物製药公司市场充满机会。

分段胜胜肽/寡核苷酸CDMO

该研究包括按产品、服务类型、最终用途和地区对全球胜肽和寡核苷酸 CDMO 的预测。

胜肽核苷酸CDMO市场洞察

Lucintel 预测，在预测期内，胜胜肽将继续成为更大的细分市场。

在预测期内，生物製药公司可能仍将占据市场的较大份额。

在预测期内，北美仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球胜肽和寡核苷酸 CDMO 市场预计将达到 50 亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球胜胜肽/寡核苷酸CDMO市场预计将以11.3%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动力是定制医疗的日益普及、对罕见疾病的兴趣增加以及对胜肽抗病毒药物的日益关注。

Q4.市场的主要细分市场是：

A4.胜肽寡核苷酸CDMO市场前景广阔，製药和生物製药公司市场充满机会。

Q5.市场的主要企业是：

A5.胜胜肽/寡核苷酸CDMO的主要企业如下：

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计胜胜肽在预测期内将继续成为更大的细分市场。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 在预测期内，北美仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球胜肽/寡核苷酸CDMO市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球胜胜肽/寡核苷酸CDMO市场趋势（2018-2023）和预测（2024-2030）
  • 全球胜胜肽/寡核苷酸 CDMO 市场（按产品）
    • 胜肽
    • 寡核苷酸
  • 按服务类型分類的全球胜胜肽/寡核苷酸 CDMO 市场
    • 合约开发
    • 契约製造
  • 按最终用途分類的全球胜肽和寡核苷酸 CDMO 市场
    • 製药公司
    • 生物製药公司
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球胜胜肽寡核苷酸 CDMO 市场（按地区）
  • 北美胜胜肽/寡核苷酸CDMO市场
  • 欧洲胜胜肽/寡核苷酸CDMO市场
  • 亚太地区胜肽和寡核苷酸CDMO市场
  • 其他区域性胜胜肽/寡核苷酸 CDMO 市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球胜胜肽寡核苷酸 CDMO 市场成长机会（按产品）
    • 按服务类型分類的全球胜肽寡核苷酸 CDMO 市场成长机会
    • 全球胜肽寡核苷酸 CDMO 市场成长机会（以最终用途）
    • 全球胜肽寡核苷酸 CDMO 市场成长机会（按地区）
  • 全球胜肽/寡核苷酸CDMO市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球胜肽和寡核苷酸 CDMO 市场的产能
    • 全球胜肽和寡核苷酸 CDMO 市场的併购和合资企业
    • 认证和许可

第七章主要企业概况

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis
简介目录

Peptide and Oligonucleotide CDMO Trends and Forecast

The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets. The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Peptide and Oligonucleotide CDMO by Segment

The study includes a forecast for the global peptide and oligonucleotide CDMO by product, service type, end use, and region.

Peptide and Oligonucleotide CDMO Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Peptides
  • Oligonucleotides

Peptide and Oligonucleotide CDMO Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

  • Contract Development
  • Contract Manufacturing

Peptide and Oligonucleotide CDMO Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Peptide and Oligonucleotide CDMO Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peptide and Oligonucleotide CDMO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide and oligonucleotide CDMO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide and oligonucleotide CDMO companies profiled in this report include-

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Peptide and Oligonucleotide CDMO Market Insights

Lucintel forecasts that peptide will remain larger segment over the forecast period.

Within this market, biopharmaceutical company will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Peptide and Oligonucleotide CDMO Market

Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).

Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the peptide and oligonucleotide CDMO market size?

Answer: The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030.

Q2. What is the growth forecast for peptide and oligonucleotide CDMO market?

Answer: The global peptide and oligonucleotide CDMO market is expected to grow with a CAGR of 11.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the peptide and oligonucleotide CDMO market?

Answer: The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

Q4. What are the major segments for peptide and oligonucleotide CDMO market?

Answer: The future of the peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.

Q5. Who are the key peptide and oligonucleotide CDMO market companies?

Answer: Some of the key peptide and oligonucleotide CDMO companies are as follows:

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6. Which peptide and oligonucleotide CDMO market segment will be the largest in future?

Answer: Lucintel forecasts that peptide will remain larger segment over the forecast period.

Q7. In peptide and oligonucleotide CDMO market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide and Oligonucleotide CDMO Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peptide and Oligonucleotide CDMO Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peptide and Oligonucleotide CDMO Market by Product
    • 3.3.1: Peptides
    • 3.3.2: Oligonucleotides
  • 3.4: Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 3.4.1: Contract Development
    • 3.4.2: Contract Manufacturing
  • 3.5: Global Peptide and Oligonucleotide CDMO Market by End Use
    • 3.5.1: Pharmaceutical Companies
    • 3.5.2: Biopharmaceutical Companies
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peptide and Oligonucleotide CDMO Market by Region
  • 4.2: North American Peptide and Oligonucleotide CDMO Market
    • 4.2.1: North American Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.2.2: North American Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.3: European Peptide and Oligonucleotide CDMO Market
    • 4.3.1: European Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.3.2: European Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.4: APAC Peptide and Oligonucleotide CDMO Market
    • 4.4.1: APAC Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.4.2: APAC Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.5: ROW Peptide and Oligonucleotide CDMO Market
    • 4.5.1: ROW Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.5.2: ROW Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Product
    • 6.1.2: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 6.1.3: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Region
  • 6.2: Emerging Trends in the Global Peptide and Oligonucleotide CDMO Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: PolyPeptide Group
  • 7.2: STA Pharmaceutical
  • 7.3: Bachem
  • 7.4: Creative Peptides
  • 7.5: Aurigene Pharmaceutical Services
  • 7.6: Merck
  • 7.7: EUROAPI
  • 7.8: Curia Global
  • 7.9: CordenPharm
  • 7.10: Sylentis